Ananda Analytical Laboratories LLC

Ananda Analytical Laboratories LLC was paid $3.79M by Medicaid between Sep 2021 and Nov 2024, across 9 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 40% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#124 of 561

Median peer was paid$222K

This provider vs. median17×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2021	7,308	$139K
2022	53,440	$1.69M
2023	24,473	$994K
2024incomplete	10,399	$972K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	40%	27,565	13,241	$1.51M
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	22%	7,539	5,141	$827K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	11%	10,136	4,691	$431K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	11%	27,318	13,157	$424K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	7.4%	2,579	2,200	$280K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	5.8%	17,452	8,761	$221K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	2.4%	2,356	1,906	$90K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	601	487	$5K
U0001	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	<1%	74	67	$2K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialNORDANYAN, GEVORK (OWNER)